Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients

(1) Background: BRAFi/MEKi are usually offered as a first line treatment for patients requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor burden, and with brain metastases. The efficacy of second line therapies after BRAFi/MEKI failure is now well defined. (2) M...

Full description

Bibliographic Details
Main Authors: Paweł Rogala, Anna M. Czarnecka, Bożena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Ziętek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Natasza Kempa-Kamińska, Joanna Seredyńska, Wiesław Bal, Katarzyna Kozak, Anna Surus-Hyla, Tomasz Kubiatowski, Grażyna Kamińska-Winciorek, Rafał Suwiński, Jacek Mackiewicz, Piotr Rutkowski
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
melanoma
immunotherapy
nivolumab
pembrolizumab
BRAF
Online Access:https://www.mdpi.com/2072-6694/14/9/2123

Internet

https://www.mdpi.com/2072-6694/14/9/2123

Similar Items